Literature DB >> 11767958

Gender and drug treatment as determinants of mortality in a cohort of heart failure patients.

A Ruigómez1, S Johansson, M A Wallander, L A García Rodríguez.   

Abstract

AIM: We assessed gender differences in the risk of mortality in heart failure (HF) patients and evaluated the association between HF drug treatment and mortality. METHODS AND
RESULTS: We identified a cohort of 820 patients with newly diagnosed HF in 1996 in UK general practices. The diagnosis of HF was confirmed by the general practitioner. Fifty per cent were females and 27% were less than 70 years old. During a mean follow-up of 2 years, 172 patients died. We used computerized records to assess risk factors and drugs prescribed as treatment. The information on severity was assessed through a questionnaire. We performed a nested case-control analysis, and observed that men had twice the risk of dying than females, however the effect of age on mortality was stronger in females than males. We found a similar interaction between HF severity and sex. Data on use of some cardiovascular drugs such as diuretics, beta-blockers ACE-inhibitors and calcium channel blockers were suggestive of a reduced mortality risk. Current use of nitrates and glycosides carried an increased risk.
CONCLUSION: Older age, male sex and severity of HF were the main predictors of mortality among HF patients. Long-term use of beta-blockers was associated with a significantly reduced risk of mortality.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11767958     DOI: 10.1023/a:1012705632049

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  30 in total

1.  Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Clinical Quality Improvement Network Investigators.

Authors: 
Journal:  Arch Intern Med       Date:  1996 Aug 12-26

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

4.  Hospital mortality in women and men with acute cardiac ischemia: a prospective multicenter study.

Authors:  B E Coronado; J L Griffith; J R Beshansky; H P Selker
Journal:  J Am Coll Cardiol       Date:  1997-06       Impact factor: 24.094

5.  Management and outcomes of congestive heart failure: a prospective study of hospitalised patients.

Authors:  J M Lowe; P M Candlish; D A Henry; J H Wlodarcyk; R F Heller; P J Fletcher
Journal:  Med J Aust       Date:  1998-02-02       Impact factor: 7.738

6.  Gender differences in survival in advanced heart failure. Insights from the FIRST study.

Authors:  K F Adams; C A Sueta; M Gheorghiade; C M O'Connor; T A Schwartz; G G Koch; B Uretsky; K Swedberg; W McKenna; J Soler-Soler; R M Califf
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

Review 7.  Heart failure: a growing public health problem.

Authors:  H Eriksson
Journal:  J Intern Med       Date:  1995-02       Impact factor: 8.989

8.  The epidemiology of heart failure: the Framingham Study.

Authors:  K K Ho; J L Pinsky; W B Kannel; D Levy
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

9.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

10.  Prevalence of heart failure in three general practices in north west London.

Authors:  J Parameshwar; M M Shackell; A Richardson; P A Poole-Wilson; G C Sutton
Journal:  Br J Gen Pract       Date:  1992-07       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.